BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
Discoveries/NILOTINIB
✓ X-VAULT VERIFIEDEXPLORATORYNOVELTY: MODERATE

NILOTINIB

Similarity bridge: nilotinib ↔ saracatinib via ABL1, KIT, PDGFRA +7 more candidate

29.0
discovery score
PubMed Studies
Novelty
Moderate
Signal
Exploratory
Sealed
May 14, 2026
BiohacksAI Hypothesis

Nilotinib may modulate the Similarity bridge: nilotinib ↔ saracatinib via ABL1, KIT, PDGFRA +7 more pathway based on its molecular target profile in the BiohacksAI corpus. This compound shows biological activity against validated targets with limited prior literature coverage, suggesting an understudied mechanism-of-action with potential research value.

Computational hypothesis based on target graph analysis. Not a confirmed mechanism. Independent experimental validation required.

Mechanism Discovery Graph
ABL1KITPDGFRAPDGFRBDDR1DDR2FRKHCKNILOTINIB
High-value target (Tier 3)
Research target (Tier 2)
Standard target
Pathway
Knowledge gap (≤5 studies)
Biological Plausibility

The Similarity bridge: nilotinib ↔ saracatinib via ABL1, KIT, PDGFRA +7 more pathway is a validated biological target area with established relevance in human disease and health research.

Nilotinib shows target overlap with compounds previously characterized in this pathway within the BiohacksAI corpus of 31,590 graph entities and 1.51M PubMed studies.

Novelty Indicators
Literature coverage
Pending ledger sync
Low coverage = higher novelty potential
Discovery score
29.00
target_count × pathway_diversity / log(studies + 2)
Mechanism area
Similarity bridge: nilotinib ↔ saracatinib via ABL1, KIT, PDGFRA +7 more
Primary biological pathway
Novelty rating
Moderate
Derived from score + literature coverage
Research Context
Literature coverage
Detailed data pending ledger sync
X-Vault timestamp
Sealed May 14, 2026 — cryptographic proof of discovery date and corpus version
Corpus scope
BiohacksAI corpus only — not a comprehensive literature or patent database search
Mechanism area
Similarity bridge: nilotinib ↔ saracatinib via ABL1, KIT, PDGFRA +7 more — computationally derived, requires experimental confirmation

This section reflects computational signal strength only. All findings require independent expert validation before any research or commercial use.

Suggested Validation Steps
1Similarity bridge: nilotinib ↔ saracatinib via ABL1, KIT, PDGFRA +7 more pathway target binding assay
2Dose-response curve (EC50 determination)
3Cellular viability and selectivity panel
4In vitro ADMET profiling

Validation roadmap is algorithmically derived from pathway context. Full experimental protocol available in Priority Signal discovery reports.

Target Relevance
ABL1
High value
KIT
Standard
PDGFRA
Standard
PDGFRB
Standard
DDR1
Standard
DDR2
Standard

Target tier based on BiohacksAI HIGH_VALUE_TARGETS registry.

Discovery Lineage
Generated byBiohacksAI Discovery Engine
Engine versionDISCOVERY_v1.2
Corpus versioncurrent
Graph entities31,590 compounds analyzed
PubMed coverage1.51M studies
Discovery dateMay 14, 2026 at 03:00 AM UTC
X-Vault Evidence SealXVAULT_v1
Discovery IDdisc_T2_nilotinib_saracatinib_a3140559
Event Hash97feb4f000f9f6f4…def46fad
Chain Hash2e80fa81eb26fbe3…5223572f
Vault Index#3011
Sealed At2026-05-14T03:00:01.493Z

Demo report — computational hypothesis only. Not validated. For X-Vault verification testing.

Full Discovery ReportLOCKED
🔒
Mechanism hypothesis (expanded)
Detailed molecular mechanism with target confidence scores and binding context
🔒
Complete target mapping
All validated molecular targets with affinity data and evidence levels
🔒
Biological pathway network
Full pathway coverage map with crosstalk and downstream effects
🔒
Graph position + related compounds
Structural neighbors in the BiohacksAI compound graph — potential analogs
🔒
Supporting PMIDs
Curated PubMed references with relevance ranking
🔒
X-Vault sealed PDF
Cryptographically verified 20-30 page discovery report

Interested in this discovery? Contact us for access and licensing details.

Contact us about this discovery →

All discoveries are computational hypothesis candidates — not confirmed mechanisms. Independent experimental validation is required before any research or commercial use. Organiq Sweden AB · BiohacksAI β